Form 4 for FLNA FILANA THERAPEUTICS, INC.
Accepted 2025-11-24 00:00:00 ET · period of report 2025-11-20 · accession 0001437749-25-036125 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2025-11-24 | 2025-11-20 | FLNA | Barry Richard | Pres, CEO, Dir | P - Purchase | $2.76 | +150.0K | 938.1K | +19% | +$414.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-20 | P | A | 150,000 | $2.76 | 938,060 | I By Trust | — | — | (F1) The purchase reported in column 4 is a weighted average price. The shares were purchased in multiple open market transactions at prices ranging from $2.74 to $2.80 per share. The reporting person undertakes to provide to Cassava, any security holder of Cassava or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each price within the range set forth in this footnote. |